VEGFR-TKIs alone or in combination with immune checkpoint inhibitors in clinical practice for the treatment of HCC

December 02, 2021 00:29:56
VEGFR-TKIs alone or in combination with immune checkpoint inhibitors in clinical practice for the treatment of HCC
COR2ED Medical Education
VEGFR-TKIs alone or in combination with immune checkpoint inhibitors in clinical practice for the treatment of HCC

Dec 02 2021 | 00:29:56

/

Show Notes

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor.

Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor.

Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option.

Other Episodes

Episode

November 20, 2023 00:29:54
Episode Cover

Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing (Video)

What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?...

Listen

Episode

December 04, 2023 00:33:58
Episode Cover

Diagnosis and management of short stature patients

Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges...

Listen

Episode 20

August 30, 2023 00:26:17
Episode Cover

Breast Cancer: Oral SERDs in ER+ breast cancer. Episode 3 - rare cases & treatment challenges

COR2ED Medical Education: In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a...

Listen